{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:35Z","timestamp":1790404835535,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.biopha.2023.115629","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:40:12Z","timestamp":1696527612000},"page":"115629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["DPP-4i versus SGLT2i as modulators of PHD3\/HIF-2\u03b1 pathway in the diabetic kidney"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-3758","authenticated-orcid":false,"given":"Emad","family":"Samaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal M.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda M.M.","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Sherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-0278","authenticated-orcid":false,"given":"Rana","family":"ElBayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2736-0850","authenticated-orcid":false,"given":"Yasmin","family":"Ghattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joly","family":"Abdlmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1713-1686","authenticated-orcid":false,"given":"Omnia","family":"Bayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7196-4892","authenticated-orcid":false,"given":"Yousef","family":"Elhusseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Maghrabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-1030","authenticated-orcid":false,"given":"Randa","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2023.115629_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00125-021-05380-z","article-title":"Hypoxia and hypoxia-inducible factors in diabetes and its complications","volume":"64","author":"Catrina","year":"2021","journal-title":"Diabetologia"},{"issue":"18","key":"10.1016\/j.biopha.2023.115629_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810413","article-title":"Hypoxia-inducible factors and diabetic kidney disease-how deep can we Go?","volume":"23","author":"Stanigut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.115629_bib3","first-page":"783","article-title":"PI3K\/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)","volume":"19","author":"Xie","year":"2019","journal-title":"Mol. Med Rep."},{"issue":"5","key":"10.1016\/j.biopha.2023.115629_bib4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1681\/ASN.2020010010","article-title":"Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors","volume":"31","author":"Packer","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115629_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"issue":"10","key":"10.1016\/j.biopha.2023.115629_bib6","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1172\/JCI137556","article-title":"Hypoxia-inducible factors and diabetes","volume":"130","author":"Gunton","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.115629_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119982","article-title":"The ameliorative effect of bromelain on STZ-induced type 1 diabetes in rats through Oxi-LDL\/LPA\/LPAR1 pathway","volume":"285","author":"Abo El-Magd","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115629_bib8","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1038\/s41598-017-11430-7","article-title":"Metformin improves endothelial function and reduces blood pressure in diabetic spontaneously hypertensive rats independent from glycemia control: comparison to vildagliptin","volume":"7","author":"Hamidi Shishavan","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2023.115629_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","article-title":"A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115629_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1681\/ASN.2010060614","article-title":"Urine albumin-to-creatinine ratio","volume":"21","author":"Kestenbaum","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115629_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3892\/etm.2017.4475","article-title":"Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes","volume":"14","author":"Zhang","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.biopha.2023.115629_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.biopha.2023.115629_bib13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000487685","article-title":"Role of calcium sensing receptor in streptozotocin-induced diabetic rats exposed to renal ischemia reperfusion injury","volume":"43","author":"Hu","year":"2018","journal-title":"Kidney Blood Press. Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.115629_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jphs.2019.06.008","article-title":"GdCl3 attenuates the glomerular sclerosis of streptozotocin (STZ) induced diabetic rats via inhibiting TGF-\u03b2\/Smads signal pathway","volume":"142","author":"Li","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2023.115629_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/MNH.0000000000000341","article-title":"Hypoxia-inducible factor activation in diabetic kidney disease","volume":"26","author":"Persson","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"12","key":"10.1016\/j.biopha.2023.115629_bib16","doi-asserted-by":"crossref","DOI":"10.2337\/db20-0457","article-title":"Relative hypoxia and early diabetic kidney disease in type 1 diabetes","volume":"69","author":"Vinovskis","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2023.115629_bib17","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pharmtox-010818-021637","article-title":"Pharmacologic targeting of hypoxia-inducible factors","volume":"59","author":"Semenza","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2023.115629_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050950","article-title":"Hypoxia, HIF, and associated signaling networks in chronic kidney disease","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115629_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s00109-007-0278-y","article-title":"Hypoxia and the HIF system in kidney disease","volume":"85","author":"Nangaku","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2023.115629_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112461","article-title":"Perspectives on the role of magnetic resonance imaging (Mri) for noninvasive evaluation of diabetic kidney disease","volume":"10","author":"Mora-Guti\u00e9rrez","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.biopha.2023.115629_bib21","article-title":"Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition","volume":"117","author":"Higgins","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.115629_bib22","article-title":"The role of hypoxia-inducible factors in metabolic diseases","volume":"Vol. 15","author":"Gonzalez","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2023.115629_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810413","article-title":"Hypoxia-inducible factors and diabetic kidney disease\u2014how deep can we go?","volume":"23","author":"Stanigut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115629_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s13105-021-00788-y","article-title":"Detrimental effects of hypoxia on glomerular podocytes","volume":"77","author":"Singh","year":"2021","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2023.115629_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-021-05380-z","article-title":"Hypoxia and hypoxia-inducible factors in diabetes and its complications","volume":"64","author":"Catrina","year":"2021","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.biopha.2023.115629_bib26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1113\/EP085292","article-title":"Metabolic aspects of high-altitude adaptation in Tibetans","volume":"100","author":"Ge","year":"2015","journal-title":"Exp. Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115629_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.biopha.2023.115629_bib28","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115629_bib29","article-title":"Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury","volume":"11","author":"Chang","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2023.115629_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129034","article-title":"Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules","volume":"5","author":"Li","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2023.115629_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.586892","article-title":"Diabetic nephropathy: novel molecular mechanisms and therapeutic targets","volume":"11","author":"Zoja","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115629_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2023.115629_bib33","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am. J. Kidney Dis."},{"issue":"5932","key":"10.1016\/j.biopha.2023.115629_bib34","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.1169956","article-title":"Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1","volume":"324","author":"Dioum","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2023.115629_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2010.05.023","article-title":"Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1\u03b1","volume":"38","author":"Lim","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2023.115629_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13961","article-title":"Interplay of adenosine monophosphate-activated protein kinase\/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: a novel conceptual framework","volume":"22","author":"Packer","year":"2020","journal-title":"Diabetes, Obes. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2023.115629_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/CS20180031","article-title":"The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin","volume":"132","author":"Kanasaki","year":"2018","journal-title":"Clin. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.115629_bib38","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.xkme.2021.07.007","article-title":"Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review","volume":"3","author":"Daza-Arnedo","year":"2021","journal-title":"Kidney Med."},{"key":"10.1016\/j.biopha.2023.115629_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00443","article-title":"The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease","volume":"6","author":"Panchapakesan","year":"2015","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115629_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-019-01765-5","article-title":"Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion\/detorsion in rats: a possible role of HIF-1\u03b1 and nitric oxide","volume":"393","author":"Abdelzaher","year":"2020","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115629_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/21691401.2019.1652624","article-title":"DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells","volume":"47","author":"Ma","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:25:08Z","timestamp":1776461108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223014270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":41,"alternative-id":["S0753332223014270"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115629","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DPP-4i versus SGLT2i as modulators of PHD3\/HIF-2\u03b1 pathway in the diabetic kidney","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115629"}}